Therapeutic Asset Ratings

320 results matching 1 filter

128,859 assets · 8,677 sponsors · 3,127 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Vancomycin melanoma	Microbiotica Ltd	P1/2	CCC (49)
1-PIPERIDINEETHANOL, .ALPHA.-((2-NITRO-1H-IMIDAZOL-1-YL)METHYL)-, HYDROCHLORIDE (1:1), (.ALPHA.R)- melanoma	Yana Najjar	P2	CCC (48)
Aguix melanoma	Brigham and Women's Hospital	P2	CCC (48)
AZD1775 melanoma	National Cancer Institute (NCI)	P2	CCC (48)
Balstilimab melanoma	Targovax Oy	P2	CCC (48)
Bendamustine Melanoma	National Cancer Institute (NCI)	P2	CCC (48)
Ceralasertib melanoma	AstraZeneca	P2	CCC (48)
Crizotinib melanoma	Charite University, Berlin, Germany	P2	CCC (48)
Dc-Cik Melanoma	The First People's Hospital of Changzhou	P2	CCC (48)
Defactinib melanoma	National Cancer Institute (NCI)	P2	CCC (48)
Domvanalimab melanoma	Diwakar Davar	P2	CCC (48)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4) melanoma	Grupo Español Multidisciplinar de Melanoma	P2	CCC (48)
Ensartinib melanoma	Memorial Sloan Kettering Cancer Center	P2	CCC (48)
Etimupepimut melanoma	Memorial Sloan Kettering Cancer Center	P2	CCC (48)
Famitinib melanoma	Shanghai Zhongshan Hospital	P2	CCC (48)
Fexagratinib melanoma	National Cancer Institute (NCI)	P2	CCC (48)
Gdc-0068 melanoma	National Cancer Institute (NCI)	P2	CCC (48)
Gdc-0449 melanoma	National Cancer Institute (NCI)	P2	CCC (48)
GSK-2636771 melanoma	National Cancer Institute (NCI)	P2	CCC (48)
her3-dxd melanoma	Daiichi Sankyo	P2	CCC (48)
human hyaluronidase isozyme-5 (HYAL5, sperm adhesion molecule 1, SPAM1, hyaluronidase PH-20, EC:3.2.1.35) fragment (3-433, 1-431 in the current sequence) engineered variant with the structural domain replaced by the corresponding region of human hyaluronidase isozyme-1 (HYAL1)(<sup>306</sup>TLSIMRSMKSCLLDDNYMETI<sup>326</sup>><sup>304</sup>SWENTRTKESCQAIKEYMDTT<sup>324</sup>), produced in Chinese hamster ovary (CHO) cells, cell line DG44, glycoform alfa Melanoma	Merck Sharp & Dohme LLC	P2	CCC (48)
ibi363 melanoma	Innovent Biologics (Suzhou) Co. Ltd.	P2	CCC (48)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER melanoma	National Cancer Institute (NCI)	P2	CCC (48)
IRON DEXTRAN melanoma	Indiana University	P2	CCC (48)
Larotrectinib melanoma	National Cancer Institute (NCI)	P2	CCC (48)

Showing 101 to 125 of 320 assets

PreviousPage 5 of 13Next